Algernon Pharmaceuticals reported that Ifenprodil was shown to reduce interleukin 6 in its Phase 2b/3 COVID-19 Study, which the company states may have positive implications for its use in its ongoing Phase 2 trial of Ifenprodil for treatment of idiopathic pulmonary fibrosis and chronic cough.read more >
Noble Capital Markets noted in a research report that shortly after receiving its largest single order to date, a 4.4-ton order for OxC-beta Livestock, Avivagen Inc. has received a new order for 4 tons per month from its representative in Mexico. read more >
McAlinden Research for Streetwise Reports (05/07/2021)
COVID-19 brought record-setting investment to the healthcare industry in 2020, but this year is shaping up to be even better, reports McAlinden Research Partners. Demand for telehealth services skyrocketed during the pandemic, and funding is starting to follow suit.
read more >
Reliq Health Technologies reported the addition of four new skilled nursing facility customers in the southern U.S. and announced plans to expand its Care Management Team to meet the growing demand for Care Management Services.read more >
Shares of Twist Bioscience Corp. traded 14% higher after the firm reported that orders in Q2/21 grew by 69% year-over-year and that it is raising its FY/21 revenue guidance to $121–129 million. read more >
BioNTech shares established a new 52-week high price after the company reported that together with its partner Pfizer it has filed a request to expand Conditional Marketing Authorization of COMIRNATY® in the EU to adolescents ages 12 to 15 for its mRNA-based SARS-CoV-2 vaccine.
read more >
Galera Therapeutics shares traded 25% higher after the company reported new data from its Phase 1/2 pilot study of dismutase mimetic GC4419 that when used in combination with radiation therapy was shown to nearly double median overall survival time in patients with locally advanced pancreatic cancer.read more >
ADMA Biologics shares traded 9% higher after the company received FDA approval for increased intravenous immune globulin production scale, allowing the firm to increase manufacturing capacity from 400,000 to 600,000 liters and achieve peak revenues of greater than $300 million. read more >
Ocugen Inc. shares traded up as much as 47% before closing just 3.66% higher for the day after the company announced a $100 million registered direct offering of common stock priced at a $10 per share, which represents a premium to the market price.read more >